HIV virological suppression influences response to the AS03-adjuvanted monovalent pandemic influenza A H1N1 vaccine in HIV-infected children

Autor:	Karina Butler, Paul Lynam, Patrick J. Gavin, Michelle Goode, Timothy Ronan Leahy
Rok vydání:	2014
Předmět:	Male Pulmonary and Respiratory Medicine Adolescent Epidemiology pandemic H1N1 influenza Population HIV Infections Booster dose Antibodies Viral Influenza A Virus H1N1 Subtype Adjuvants Immunologic Influenza Human Pandemic Humans Medicine Prospective Studies AS03 Seroconversion Child Adverse effect education education.field_of_study business.industry Public Health Environmental and Occupational Health HIV virus diseases Original Articles Hemagglutination Inhibition Tests vaccination Vaccination Regimen Infectious Diseases Influenza Vaccines Child Preschool AS03 adjuvant Immunology Female business Ireland
Zdroj:	Influenza and Other Respiratory Viruses
ISSN:	1750-2640
DOI:	10.1111/irv.12243
Popis:	Design Children with HIV are especially susceptible to complications from influenza infection, and effective vaccines are central to reducing disease burden in this population. We undertook a prospective, observational study to investigate the safety and immunogenicity of the inactivated split-virion AS03-adjuvanted pandemic H1N1(2009) vaccine in children with HIV. Setting National referral centre for Paediatric HIV in Ireland. Sample Twenty four children with HIV were recruited consecutively and received two doses of the vaccine. The serological response was measured before each vaccine dose (Day 0 and Day 28) and 2 months after the booster dose. Antibody titres were measured using a haemagglutination inhibition (HAI) assay. Seroprotection was defined as a HAI titre ≥ 1:40; seroconversion was defined as a ≥ fourfold increase in antibody titre and a postvaccination titre ≥ 1:40. Main outcome measures The seroconversion rates after prime and booster doses were 75% and 71%, respectively. HIV virological suppression at the time of immunization was associated with a significantly increased seroconversion rate (P = 0·009), magnitude of serological response (P = 0·02) and presence of seroprotective HAI titres (P = 0·017) two months after the booster dose. No other factor was significantly associated with the seroconversion/seroprotection rate. No serious adverse effects were reported. Vaccination had no impact on HIV disease progression. The AS03-adjuvanted pandemic H1N1 vaccine appears to be safe and immunogenic among HIV-infected children. A robust serological response appears to be optimized by adherence to a HAART regimen delivering virological suppression.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af1ed76ea3f9926203676a261919025e https://doi.org/10.1111/irv.12243 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.